Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM5 | P41594 | 2/20 | 0.49 |
| ▸ | CTPS1 | P17812 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | GRM4 | Q14833 | 5/20 | 0.42 |
| ▸ | RAB9A | P51151 | 4/20 | 0.41 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.39 |
| ▸ | NPC1 | O15118 | 3/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | PKM | P14618 | 1/20 | 0.39 |
| ▸ | ABL1 | P00519 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL233471 | 0.85 | GRM5 (0.49) | GRM5CTPS1SMN1; SMN2KDM4EGRM4 | |
| SCHEMBL231811 | 0.84 | ALDH1A1 (0.54) | GRM5SMN1; SMN2KDM4EALDH1A1RAB9A | |
| SCHEMBL106793 | 0.76 | ALDH1A1 (0.61) | GRM5SMN1; SMN2KDM4EALDH1A1MAPT | |
| SCHEMBL29735357 | 0.76 | ALDH1A1 (0.61) | GRM5SMN1; SMN2KDM4EALDH1A1MAPT | |
| SCHEMBL15238558 | 0.74 | KDM4E (0.59) | GRM5SMN1; SMN2KDM4EALDH1A1GRM4 | |
| SCHEMBL230744 | 0.73 | MAP3K5 (0.57) | — | |
| SCHEMBL15238517 | 0.71 | NPC1 (0.59) | GRM5SMN1; SMN2KDM4EALDH1A1RAB9A | |
| SCHEMBL1529765 | 0.71 | CES2 (0.59) | CTPS1SMN1; SMN2KDM4EALDH1A1RAB9A | |
| SCHEMBL14809955 | 0.70 | KDM4E (0.61) | GRM5SMN1; SMN2KDM4EALDH1A1 | |
| SCHEMBL13188319 | 0.70 | KDM4E (0.66) | GRM5SMN1; SMN2KDM4EALDH1A1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-RE48150-E1 | Apoptosis signal-regulating kinase inhibitors | GILEAD SCIENCES, INC. (US) | 2020-08-11 | — | — | US | disclosed |
| EP-2588475-B1 | APOPTOSIS SIGNAL-REGULATING KINASE INHIBITORS | GILEAD SCIENCES INC (US) | 2015-05-20 | — | — | EP | disclosed |
| US-8927582-B2 | Apoptosis signal-regulating kinase inhibitors | GILEAD SCIENCES, INC. (US) | 2015-01-06 | — | — | US | disclosed |
| US-20130203819-A1 | APOPTOSIS SIGNAL-REGULATING KINASE INHIBITORS | GILEAD SCIENCES, INC. (US) | 2013-08-08 | — | — | US | disclosed |
| US-8440665-B2 | Apoptosis signal-regulating kinase inhibitors | GILEAD SCIENCES, INC. (US) | 2013-05-14 | — | — | US | disclosed |
| EP-2588475-A1 | APOPTOSIS SIGNAL-REGULATING KINASE INHIBITORS | Gilead Sciences, Inc. (US) | 2013-05-08 | — | — | EP | disclosed |
| US-20120004267-A1 | APOPTOSIS SIGNAL-REGULATING KINASE INHIBITORS | GILEAD SCIENCES, INC. (US) | 2012-01-05 | — | — | US | disclosed |
| WO-2012003387-A1 | APOPTOSIS SIGNAL-REGULATING KINASE INHIBITORS | GILEAD SCIENCES, INC. (US) | 2012-01-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130203819-A1 | APOPTOSIS SIGNAL-REGULATING KINASE INHIBITORS | AIFM1, MAP3K1, RIPK3 | GRM5 3196/4885CTPS1 3634/4885SMN1; SMN2 1776/4885 |
| US-20120004267-A1 | APOPTOSIS SIGNAL-REGULATING KINASE INHIBITORS | AIFM1, MAP3K1, RIPK3 | GRM5 3196/4885CTPS1 3634/4885SMN1; SMN2 1776/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.